Breaking Down the VERIFY Trial for Patients With Polycythemia Vera
Dr. Aaron Gerds breaks down the outcomes of the phase 3 VERIFY trial, investigating rusfertide, for patients with polycythemia vera, a type of blood cancer.
Watch
What Should Patients With Lung Cancer Know After ASCO 2025?
Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.
Bringing Light to More Personalized Medicine in Lung Cancer After ASCO 2025
Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.
A New Therapeutic Approach May Make Waves in Kidney Cancer Treatment
Dr. Michael Serzan provides expert takeaways on treatment updates for patients with early-stage kidney cancer following the 2025 ASCO Meeting.
What Patients With Genitourinary Cancers Should Know After ASCO 2025
Dr. Joshua K. Sabari sat down with Dr. Daniel V. Araujo to discuss topline takeaways from the 2025 ASCO Meeting across the realm of genitourinary oncology
How to Prepare for Self-Advocacy After a Cancer Diagnosis
Patients can prepare for self-advocacy by bringing personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner.
Enhertu Combo May Offer Longer Control for HER2+ Breast Cancer
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
The VERIFY trial explores rusfertide to manage polycythemia vera without causing iron deficiency symptoms, Dr. Aaron Gerds explained.
You Are Not Alone While Building a Support Team During Cancer Care
Michelle Kirschner discusses the how patients can foster a strong network of supporters from diagnosis through survivorship.
Protect Your Healing by Lowering Chemical Exposure After Cancer Diagnosis
It is important to understand why it is vital that patients and survivors of cancer take steps to reduce the body’s burden both before and after treatment.
Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas.
Understanding Supportive Care Needs in Younger Women With Cancer
Natalie Schnaitmann discusses urgent supportive care gaps younger women with cancer encounter, and how they affect long-term quality of life.
New or Persistent Acid Reflux May Signal Esophageal Cancer Risk
New or persistent acid reflux, especially after age 50, may mean higher risk for esophageal cancer, particularly in people with other known risk factors.
Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Understanding the Side Effects of RLY-2608 in HR+, HER2– Breast Cancer
Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer.
Fotivda Monotherapy Demonstrated Efficacy in Previously Treated Metastatic RCC
Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma.
Delving into the Evaluation of JNJ-1900 Trial for Lung Cancer Treatment
Dr. Jared Weiss sat down for an interview to discuss a trial evaluating JNJ-1900, an immune-stimulating radiation sensitizer, in those with lung cancer.
Expanding Access to Screening May Help Prevent Esophageal Cancer
Minimally invasive screening methods offer a more accessible, cost-effective way to detect Barrett’s esophagus early and help prevent esophageal cancer.
Gene Variant May Predict Side Effects From Kidney Cancer Immunotherapy
A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.
How Essential Thrombocythemia and Polycythemia Vera Affect Blood Flow
Dr. Tiziano Barbui explains how excess blood cell production in certain myeloproliferative neoplasms can impair circulation and why treatments like phlebotomy are used.
IDH Inhibitors Offer New, Safer Option for Some Brain Tumors
IDH inhibitors, now FDA approved for lower-grade gliomas, yield fewer side effects than chemotherapy, said Dr. Ryan Merrell.
Uniting Pediatric and Adult Oncologists to Advance AYA Lymphoma Care
Dr. Andrew M. Evens discusses some of the recent research advancements in AYA lymphoma care that have emerged through clinical trials and initiatives.
Expert Offers Surveillance, Lifestyle Guidance After CRC, Anal Cancer
Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.
Understanding the Evolution of Waldenström Macroglobulinemia Treatment
Dr. Shirley D’Sa discusses how treatment strategies for WM have evolved over the course of her career.
Early Arterial Thrombosis May Signal Future Cancer Risk
Arterial thrombosis may occur years before cancer diagnosis, suggesting it could be a risk factor, according to Dr. Tiziano Barbui.
What are the Long-Term Side Effects of Proton Therapy in Prostate Cancer?
Proton therapy may reduce urinary, bowel and sexual side effects in prostate cancer by minimizing radiation exposure to healthy tissue, per Dr. Curtiland Deville Jr.
Facing Cancer as an AYA and Navigating Fertility Preservation Choices
Carly Stafford Dixon, discusses how she approached fertility preservation after her diagnosis of primary mediastinal b-cell lymphoma, a rare blood cancer.
Tagrisso Therapy Elicits Wave of New Therapeutic Approaches in NSCLC
Dr. Suresh Ramalingam discussed how the LAURA findings support the role of Tagrisso as a backbone therapy across multiple settings in EGFR-mutated NSCLC.
Understanding Unique Treatment Options Across Bladder Cancer Care
Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease stage and type.
Preparing For Survivorship After Lymphoma Treatment in AYA Patients
Dr. Kara Kelly discusses specific long-term health considerations that AYA survivors of lymphoma should be aware of to best prepare for survivorship.
